Literature DB >> 17999123

Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis.

Alfredo Guglielmi1, Andrea Ruzzenente, Alessandro Valdegamberi, Silvia Pachera, Tommaso Campagnaro, Mirko D'Onofrio, Enrico Martone, Paola Nicoli, Calogero Iacono.   

Abstract

BACKGROUND AND AIMS: Percutaneous radiofrequency ablation (RFA) demonstrated good results for the treatment of hepatocellular carcinoma (HCC) in cirrhotic patients; it is still not clear whether the overall survival and disease-free survival after RFA are comparable with surgical resection. The aims of this study are to compare the overall survival and disease-free survival in two groups of cirrhotic patients with HCC submitted to surgery or RFA.
METHODS: Two hundred cirrhotic patients with HCCs smaller than 6 cm were included in this retrospective study: 109 underwent RFA and 91 underwent surgical resection at a single Division of Surgery of University of Verona.
RESULTS: Median follow-up time was 27 months. Overall survival was significantly longer in the resection group in comparison with the RFA group with a median survival of 57 and 28 months, respectively (P=0.01). In Child-Pugh class B patients and in patients with multiple HCC, survival was not significantly different between the two groups. In patients with HCC smaller than 3 cm, the overall survival and disease-free survival for RFA and resection were not significantly different in univariate and multivariate analysis. Whereas in patients with HCC greater than 3 cm, surgery showed improvement in outcome in both univariate and multivariate analysis.
CONCLUSIONS: Surgical resection significantly improves the overall survival and disease-free survival in comparison with RFA. In a selected group of patients (Child-Pugh class B, multiple HCC, or in HCC<or=3 cm), the results between the two treatments did not show significant differences.

Entities:  

Mesh:

Year:  2007        PMID: 17999123     DOI: 10.1007/s11605-007-0392-8

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  22 in total

1.  Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified?

Authors:  Ronnie Tung Ping Poon; Sheung Tat Fan; Chung Mau Lo; Chi Leung Liu; Chi Ming Lam; Wai Kei Yuen; Chun Yeung; John Wong
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

2.  Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function.

Authors:  Sung Noh Hong; Sun-Young Lee; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo; Jong Chul Rhee; Dongil Choi; Hyo Keun Lim; Kwang-Woong Lee; Jae Won Joh
Journal:  J Clin Gastroenterol       Date:  2005-03       Impact factor: 3.062

3.  Long-term results of living-related donor liver graft transplantation: a single-center analysis of 110 transplants.

Authors:  Y Hashikura; S Kawasaki; M Terada; T Ikegami; Y Nakazawa; K Urata; H Chisuwa; A Mita; Y Ohno; S Miyagawa
Journal:  Transplantation       Date:  2001-07-15       Impact factor: 4.939

4.  Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old.

Authors:  Kojiro Taura; Iwao Ikai; Etsuro Hatano; Hideaki Fujii; Naoki Uyama; Yasuyuki Shimahara
Journal:  Ann Surg       Date:  2006-08       Impact factor: 12.969

Review 5.  Hepatocellular carcinoma: current management and future trends.

Authors:  Brian I Carr
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

6.  Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value.

Authors:  G L Grazi; G Ercolani; F Pierangeli; M Del Gaudio; M Cescon; A Cavallari; A Mazziotti
Journal:  Ann Surg       Date:  2001-07       Impact factor: 12.969

7.  Intrahepatic metastases in hepatocellular carcinoma: evidence for spread via the portal vein as an efferent vessel.

Authors:  A Toyosaka; E Okamoto; M Mitsunobu; T Oriyama; N Nakao; K Miura
Journal:  Am J Gastroenterol       Date:  1996-08       Impact factor: 10.864

8.  Radiofrequency ablation of hepatocellular carcinoma in cirrhotic patients.

Authors:  Alfredo Guglielmi; Andrea Ruzzenente; Arrigo Battocchia; Angelo Tonon; Girolamo Fracastoro; Claudio Cordiano
Journal:  Hepatogastroenterology       Date:  2003 Mar-Apr

Review 9.  Thermal ablative therapy for malignant liver tumors: a critical appraisal.

Authors:  Kelvin Kwok-Chai Ng; Chi-Ming Lam; Ronnie Tung-Ping Poon; Victor Ai; Wai-Kuen Tso; Sheung-Tat Fan
Journal:  J Gastroenterol Hepatol       Date:  2003-06       Impact factor: 4.029

10.  Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver.

Authors:  Marco Vivarelli; Alfredo Guglielmi; Andrea Ruzzenente; Alessandro Cucchetti; Roberto Bellusci; Claudio Cordiano; Antonino Cavallari
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

View more
  38 in total

1.  A prognostic model and treatment strategy for intrahepatic recurrence of hepatocellular carcinoma after curative resection.

Authors:  Yuzo Umeda; Hiroaki Matsuda; Hiroshi Sadamori; Hiroyoshi Matsukawa; Takahito Yagi; Toshiyoshi Fujiwara
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

Review 2.  Complications after percutaneous ablation of liver tumors: a systematic review.

Authors:  Eylon Lahat; Rony Eshkenazy; Alex Zendel; Barak Bar Zakai; Mayan Maor; Yael Dreznik; Arie Ariche
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

3.  Radiofrequency ablation in the treatment of small hepatocellular carcinoma: a meta analysis.

Authors:  Jun-Guo Liu; Yi-Jun Wang; Zhi Du
Journal:  World J Gastroenterol       Date:  2010-07-21       Impact factor: 5.742

4.  Percutaneous radiofrequency ablation versus partial hepatectomy for multicentric small hepatocellular carcinomas: a nonrandomized comparative study.

Authors:  Wei-Xing Guo; Bo Zhai; Eric C H Lai; Nan Li; Jie Shi; Wan-Yee Lau; Meng-Chao Wu; Shu-Qun Cheng
Journal:  World J Surg       Date:  2010-11       Impact factor: 3.352

Review 5.  Radiofrequency ablation versus resection for liver tumours: an evidence-based approach to retrospective comparative studies.

Authors:  Gianpiero Gravante; John Overton; Roberto Sorge; Neil Bhardwaj; Matthew S Metcalfe; David M Lloyd; Ashley R Dennison
Journal:  J Gastrointest Surg       Date:  2011-02       Impact factor: 3.452

6.  A measure to assess the ablative margin using 3D-CT image fusion after radiofrequency ablation of hepatocellular carcinoma.

Authors:  Hui Tang; Yunqiang Tang; Jian Hong; Tiejun Chen; Cong Mai; Peng Jiang
Journal:  HPB (Oxford)       Date:  2014-10-24       Impact factor: 3.647

Review 7.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

8.  Locoregional treatment for hepatocellular carcinoma: The best is yet to come.

Authors:  Naveen Kalra; Pankaj Gupta; Yogesh Chawla; Niranjan Khandelwal
Journal:  World J Radiol       Date:  2015-10-28

Review 9.  Ablation therapy for hepatocellular carcinoma: past, present and future perspectives.

Authors:  David J Niemeyer; Kerri A Simo; David A Iannitti; Iain H McKillop
Journal:  Hepat Oncol       Date:  2013-12-20

10.  Major complications after radiofrequency ablation for liver tumors: analysis of 255 patients.

Authors:  Wen-Tao Kong; Wei-Wei Zhang; Yu-Dong Qiu; Tie Zhou; Jun-Lan Qiu; Wei Zhang; Yi-Tao Ding
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.